California is home to roughly 1.4 million veterans — the largest veteran population of any state — anchored by Camp Pendleton, Naval Base San Diego, Twentynine Palms, and Travis AFB, and served by some of the largest VA systems in the country, including VA Greater Los Angeles. Scale cuts both ways: the VA's standard of care — SSRIs, prazosin, trauma-focused therapy — works for many patients, but a substantial fraction experience inadequate response, intolerable side effects, or waits that stretch months, particularly outside the major metro systems.
The clinical evidence specifically for veterans is real and growing. Albott et al. (2018, Journal of Clinical Psychiatry) studied repeated IV ketamine infusions in veterans with comorbid PTSD and treatment-resistant depression and found significant, durable symptom reductions on both dimensions. Feder et al. (2014, JAMA Psychiatry) demonstrated ketamine's efficacy for chronic PTSD specifically. Ongoing RAND and VA cooperative studies are extending this evidence base.
The mechanism matters here. Ketamine drives glutamate-mediated neuroplasticity in the days following each session, opening a window where rigid trauma-response patterns (hypervigilance, intrusive memories, avoidance) become more malleable. For veterans engaged in concurrent trauma-focused therapy — PE, CPT, EMDR — this neuroplasticity window can substantially accelerate progress that would otherwise take years.